Sun Pharmaceutical Industries Ltd. News and Updates

Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Sun Pharmaceutical Industries Ltd. from all sources in a single place.

Load latest

Sun Pharmaceutical Industries Ltd.

11 Jul 2018

1731.80

1.41%

Sun Pharma unit files patent case against German firm

livemint

DUSA has also alleged that the Germany-based Biofrontera improperly obtained confidential information from former employees

Number of FII/FPI investors increased from 1310 to 1351 in Mar 2025 qtr.

Sun Pharmaceutical Industries Ltd.

25 Jun 2018

1731.80

1.41%

Sun Pharma nears 52-week high as stock surges 32% in five weeks

Business Standard

The stock was trading 2% higher at Rs 587 on the BSE in otherwise subdued market, trading nears to 52-week high of Rs 609 touched on February 12, 2018.

Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings

Sun Pharmaceutical Industries Ltd.

20 Jun 2018, 06:55PM

1731.80

1.41%

Sun Pharma sharpens R&D; for efficiencies with digital applications

Business Standard

The drug maker has guided for an increase in R&D expenses in FY 19 as it builds a pipeline of specialty products

Number of FII/FPI investors increased from 1310 to 1351 in Mar 2025 qtr.

Sun Pharmaceutical Industries Ltd.

19 Jun 2018

1731.80

1.41%

Sun Pharma

Hold: Sun Pharmaceutical Industr...

Recommendation Target

Geojit BNP Paribas

We expect revenue/Adj.PAT to grow at 14%/42% CAGR over FY18-20E driven by expected pick-up in US sales and key speciality & generic launches. Given improved visibility for key drug launches in the US post Halol plant resolution, increased spend on specialty business and expected recovery in India business, we change our rating to HOLD' from SELL'. Our revised target price stands at Rs597 based on 23x FY20E PE. Weak US and subdued India sales drags revenue Sun Pharma reported 2% YoY decline in net revenue in Q4FY18 due to weak US sales which declined by...

Sun Pharmaceutical Industries Ltd. is trading above its 50 day SMA of 1730.6

Sun Pharmaceutical Industries Ltd.

14 Jun 2018

1731.80

1.41%

Sun Pharma shows signs of bottom formation

Business Line

Sun Pharmaceutical Industries, which has lost more than a third of its market capitalisation in the last three years, shows signs of reversal in downt

Number of FII/FPI investors increased from 1310 to 1351 in Mar 2025 qtr.

USFDA nod to Sun Pharma's Halol plant a big boost for Indian pharma

Business Today | 13 Jun 2018 7 more

Sun Pharmaceutical Industries Ltd.

13 Jun 2018

1731.80

1.41%

Pharmaceuticals (Update): Comeback on the cards

Buy: Sun Pharmaceutical Industr...

Recommendation Target

HDFC Securities

We believe FY19 may see a gradual comeback for large cap pharma companies, driven by (1) Actual and likely regulatory resolutions, (2) Moderating price erosion and (3) Several product launches across generic and specialty categories in 2HFY19. We believe earnings have bottomed out, while the base is favourable. Upgrade Sun Pharma to BUY. Beleaguered by regulatory clampdowns, channel consolidation in the US and increased competition, earnings of US-focused Indian pharma companies dropped 30% over FY18. Despite the all-too-visible business challenges, they persisted with higher R&D; activity (related to complex generics and specialty business), which aggravated the pain. As a result, the NIFTY Pharma index has corrected ~30% over three years (after 30% CAGR over FY11-15).

Sun Pharmaceutical Industries Ltd. is trading below its 30 day SMA of 1747.4

Sun Pharmaceutical Industries Ltd.

11 Jun 2018

1731.80

1.41%

Sun Pharma's Halol plant resolution could repair more than its financial health

livemint

The resolution of Sun Pharma's Halol plant could add as much as $100 million in revenues annually

Number of FII/FPI investors increased from 1310 to 1351 in Mar 2025 qtr.

Sun Pharmaceutical Industries Ltd.

09 Jun 2018

1731.80

1.41%

Sun Pharma stock gains 8% as company clears FDA's Halol plant hurdle

Business Standard

The Halol plant was reinspected by the FDA in the March quarter, and had received three Form 483 observations

Sun Pharmaceutical Industries Ltd. is trading below its 30 day SMA of 1747.4

Sun Pharma's Halol plant to get clearance soon

Business Today | 08 Jun 2018 1 more

Sun Pharmaceutical Industries Ltd.

08 Jun 2018

1731.80

1.41%

Halol resolution in sight; status changed to VAI

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

6 March 2018 The Halol facility received 23 483 observations post US FDA inspection in September 2014. Later, in December 2015, US FDA had issued a warning letter for the facility. In November/December 2016, US FDA re- inspected the facility and issued nine 483 observations and maintained OAI status. In February 2018, US FDA re-inspected the facility, and this time, issued three 483 observations, with no data integrity issue and no repeat observation, following which it received VAI status today (Link). SUNPs US business has been under pressure since the warning letter, as it has not received any product approval from this facility in three and a half years. The facility contributes 8-10% of US sales for SUNP, currently down from >15% at the time of warning letter. Resolution of the Halol issue is critical for the company, as it would provide visibility on key approvals including Xelpros, Elepsia, Vagifem, etc.